Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

• click to rate

  Posted by Two Blokes Jun 20 - Filed in Stock - 3 views
  
  Capricor Therapeutics CAPR on Friday released four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD).